anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Unsupported Upper Limb Exercise Test (UULEX):Individual sit on the chair in a way that touches the wall with the lines of the UULEX. The tables of the UULEX contain 8 horizontal levels. Each level is 84 cm wide and 8 cm high. The distance between the level centers is 15 cm. The line below corresponds to the knee level of the participant. The individual moves the plastic bar, which has a weight of 0.2 kg, from the hips by holding the arms at the shoulder width and moves it to the different levels of the lines of the UULEX in front of it. Each movement starts at the hip joint and ends at the hip joint. After making the first level for two minutes, the upper levels are made in two minute. The beginning and end point of each level is the hip joint. The bar is removed until 30 movements per minute accompanied by a metronome (level up). When individuals reach their maximum height, the bar weighing 0.2 kg is replaced with a 0.5 kg weighted bar. This weight will continue to raise to the maximum height. The weight is then increased by 0.5 kg per minute to 2 kg. Individual is referred to the test to continue until symptom limitation.

Statistical Analyses:The data will be given as mean ± standard deviation (X ± SD). The Intraclass Correlation Coefficient (ICC) will be used to evaluate the reliability of the UULEX. For concurrent validity, the relationship of the 30 sec Push up-Pull Test, DASH, HAQ and the 6-peg board ring test will be evaluated with Pearson correlation analysis. In our study, 85% power was obtained in the design made with 5% type 1 error and at least 70 patients. p value will be taken as 0.05.
A device and method is provided for the detection of diabetes in a person using pulse palpation signals. The pulse palpation signal is captured from the radial artery of the person using a photo-plethysmograph (PPG) sensor. The PPG signal is then preprocessed by a processor. The preprocessed PPG signal is then analyzed by the processor to detect the peak in the PPG signal. The detected peaks are used to extract a first set of feature parameters. The first of feature parameters are compared with a second set of feature parameters, wherein the second set of feature parameters are extracted from the control group of individuals. Based on the comparison it is detected that the person is one of in normal condition, pre-diabetic condition or a diabetic condition. According to another embodiment, the invention also provides a method to determine the severity index and progression risk of diabetes in the person.
BACKGROUND: Advanced adenomas (AAs) with high-grade dysplasia (HGD) represent a risk factor for metachronous neoplasia, with guidelines recommending short-interval surveillance. Although the worse prognosis of proximal (vs distal) colon cancers (CCs) is established, there is paucity of evidence on the impact of laterality on the risk of subsequent neoplasia for these AAs.
METHODS: Adults with HGD adenomas undergoing polypectomy were identified in the Surveillance, Epidemiology, and End Results database (2000-2019). Cumulative incidence of malignancy was estimated using the Kaplan-Meier method. Fine-Gray models assessed the effect of patient and disease characteristics on CC incidence.
RESULTS: Of 3199 patients, 26% had proximal AAs. A total of 65 cases of metachronous adenocarcinoma were identified after polypectomy of 35 proximal and 30 distal adenomas with HGD. The 10-year cumulative incidence of CC was 2.3%; when stratified by location, it was 4.8% for proximal vs 1.4% for distal adenomas. Proximal location was significantly associated with increased incidence of metachronous cancer (adjusted hazard ratio, 3.32; 95% CI, 2.05-5.38).
CONCLUSION: Proximal location of AAs with HGD was associated with >3-fold increased incidence of metachronous CC and shorter time to diagnosis. These data suggest laterality should be considered in the treatment and follow-up of these patients.
Subjects will be randomized to receive analgesia-first sedation by intermittent doses of Fentanyl (25 mcg), instead of continuous IV infusions. If the intermittent IVP x4 fails to achieve the target pain score, an infusion starts at 50 mcg/hr and titration by 25 mcg q15 minutes. If sedation score is not achieved, propofol infusion starts at 5 mcg/kg/min to achieve goal RASS of 0 to -2. Subjects will be assessed for a ventilator weaning trial daily.
PURPOSE: The present study aimed to characterize the exercise-induced neuromuscular fatigue and its possible links with cerebral and muscular oxygen supply and utilization to provide mechanistic insights into the reduced exercise capacity characterizing patients with end-stage renal disease (ESRD).
METHODS: Thirteen patients with ESRD and thirteen healthy males (CTR group) performed a constant-force sustained isometric contraction at 50% of their maximal voluntary isometric contraction (MVC) until exhaustion. Quadriceps muscle activation during exercise was estimated from vastus lateralis, vastus medialis, and rectus femoris EMG. Central and peripheral fatigue were quantified via changes in pre- to postexercise quadriceps voluntary activation (ΔVA) and quadriceps twitch force (ΔQtw,pot) evoked by supramaximal electrical stimulation, respectively. To assess cerebral and muscular oxygenation, throughout exercise, near-infrared spectroscopy allowed investigation of changes in oxyhemoglobin (∆O2Hb), deoxyhemoglobin (∆HHb), and total hemoglobin (∆THb) in the prefrontal cortex and in the vastus lateralis muscle.
RESULTS: ESRD patients demonstrated lower exercise time to exhaustion than that of CTR (88.8 ± 15.3 s and 119.9 ± 14.6 s, respectively, P < 0.01). Following the exercise, MVC, Qtw,pot, and VA reduction were similar between the groups (P > 0.05). There was no significant difference in muscle oxygenation (∆O2Hb) between the two groups (P > 0.05). Cerebral and muscular blood volume (∆THb) and oxygen extraction (∆HHb) were significantly blunted in the ESRD group (P < 0.05). A significant positive correlation was observed between time to exhaustion and cerebral blood volume (∆THb) in both groups (r2 = 0.64, P < 0.01).
CONCLUSIONS: These findings support cerebral hypoperfusion as a factor contributing to the reduction in exercise capacity characterizing ESRD patients.
The application discloses a fusion protein LbtA5 and application thereof in preparation of malignant melanoma medicaments. The application protects a fusion protein named fusion protein LbtA5, which comprises the following two sections: annexin A5 and lebestatin. Specifically, the fusion protein is SEQ ID NO:1, and a protein shown in the formula 1. The application also protects the application of any one of the fusion proteins in preparing a medicament for treating melanoma. The application also provides the application of the fusion protein in preparing proliferation inhibitor and/or migration inhibitor aiming at melanoma cells. The application has great value for developing medicines for treating malignant melanoma.
Salbutamol is a bronchodilator that relaxes the muscles of the airways and increases the flow of air to the lungs. With the aid of a spacer, 400mcg of the drug will be administered once during the protocol.
Introvale is dispensed in an Extended-Cycle Blister Card [see How Supplied/Storage and Handling (16)]. Introvale should be started on a Sunday ( see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.

Instruct patients to take Introvale once a day by mouth at the same time every day for 91 days. To achieve maximum contraceptive effectiveness, Introvale should be taken exactly as directed and at intervals not exceeding 24 hours. For patient instructions regarding missed pills, see FDA-approved patient labeling.
A method for treating background and precancerous diseases of cervix uteri provides for the destructive procedures and the administration of the drugs. In the background pathology, prior to electroexcision the vagina is sanitized with Fluomyzin suppositories (three suppositories before menstruation and three – just before electroexcision. Straight after the excision, anti-burn collagenous sponge is applied for three days. On Days 4 and 7, the wound-healing sponge is applied onto the wound surface. Since Day 10, Genferon suppositories are administered (500,000 twice a day for 10 days). When the normal microflora is restored, the vaginal suppositories Ginoflor are applied for 6 days once a day. In the cases of the advanced leukoplakia or precancerous lesions, first Laferon is administered topically intracervically at a dose of 3 million IU #10 daily at the sites corresponding to 12, 3, 6, 9 hours marks clockwise starting 10-12 days before menstruation. When indicated, te therapy is reinforced with Genferon suppositories 500,000 before the night sleep and Eligen spray 2-3 times a day for a month.
The increasing burden of Alzheimer's disease (AD) emphasizes the need for effective diagnostic and therapeutic strategies. Despite available treatments targeting amyloid beta (Aβ) plaques, disease-modifying therapies remain elusive. Early detection of mild cognitive impairment (MCI) patients at risk for AD conversion is crucial, especially with anti-Aβ therapy. While plasma biomarkers hold promise in differentiating AD from MCI, evidence on predicting cognitive decline is lacking. This study's objectives were to evaluate whether plasma protein biomarkers could predict both cognitive decline in non-demented individuals and the conversion to AD in patients with MCI. This study was conducted as part of the Korean Longitudinal Study on Cognitive Aging and Dementia (KLOSCAD), a prospective, community-based cohort. Participants were based on plasma biomarker availability and clinical diagnosis at baseline. The study included MCI (n = 50), MCI-to-AD (n = 21), and cognitively unimpaired (CU, n = 40) participants. Baseline plasma concentrations of six proteins-total tau (tTau), phosphorylated tau at residue 181 (pTau181), amyloid beta 42 (Aβ42), amyloid beta 40 (Aβ40), neurofilament light chain (NFL), and glial fibrillary acidic protein (GFAP)-along with three derivative ratios (pTau181/tTau, Aβ42/Aβ40, pTau181/Aβ42) were analyzed to predict cognitive decline over a six-year follow-up period. Baseline protein biomarkers were stratified into tertiles (low, intermediate, and high) and analyzed using a linear mixed model (LMM) to predict longitudinal cognitive changes. In addition, Kaplan-Meier analysis was performed to discern whether protein biomarkers could predict AD conversion in the MCI subgroup. This prospective cohort study revealed that plasma NFL may predict longitudinal declines in Mini-Mental State Examination (MMSE) scores. In participants categorized as amyloid positive, the NFL biomarker demonstrated predictive performance for both MMSE and total scores of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-TS) longitudinally. Additionally, as a baseline predictor, GFAP exhibited a significant association with cross-sectional cognitive impairment in the CERAD-TS measure, particularly in amyloid positive participants. Kaplan-Meier curve analysis indicated predictive performance of NFL, GFAP, tTau, and Aβ42/Aβ40 on MCI-to-AD conversion. This study suggests that plasma GFAP in non-demented participants may reflect baseline cross-sectional CERAD-TS scores, a measure of global cognitive function. Conversely, plasma NFL may predict longitudinal decline in MMSE and CERAD-TS scores in participants categorized as amyloid positive. Kaplan-Meier curve analysis suggests that NFL, GFAP, tTau, and Aβ42/Aβ40 are potentially robust predictors of future AD conversion.
INTRODUCTION: Outcomes for pineal region and superior cerebellar tumors in young children often hinge on extent of microsurgical resection, and thus choosing an approach that provides adequate visualization of pathology is essential. The occipital interhemispheric transtentorial (OITT) approach provides excellent exposure while minimizing cerebellar retraction. However, this approach has not been widely accepted as a viable option for very young children due to concerns for potential blood loss when incising the tentorium. The aim of this paper is to characterize our recent institutional experience with the occipital interhemispheric transtentorial approach (OITT) for tumor resection in infants and toddlers.
METHODS: A retrospective study was performed between 2016 and 2023 of pediatric patients less than 36 months of age who underwent OITT for tumor resection at a high-volume referral center. Patients with at least 3 months of postoperative follow-up and postoperative MRI were included. Primary outcomes included extent of resection, intraoperative and postoperative complications, and neurologic outcome. Secondary outcomes included length of stay and estimated blood loss.
RESULTS: Eight patients, five male, were included. The median age at the time of surgery was 10 months (range 5-36 months). Presenting symptoms included macrocephaly, nausea/vomiting, strabismus, gait instability, or milestone regression. Hydrocephalus was present preoperatively in all patients. Average tumor volume was 38.6 cm3, ranging from 1.3 to 71.9 cm3. All patients underwent an OITT approach for tumor resection with stereotactic guidance. No intraoperative complications occurred, and no permanent neurologic deficits developed postoperatively. Gross total resection was achieved in all cases per postoperative MRI report, and no instances of new cerebellar, brainstem, or occipital lobe ischemia were noted.
CONCLUSIONS: OITT approach for tumor resection in very young children (≤ 36 months) is an effective strategy with an acceptable safety profile. In our series, no significant intraoperative or postoperative complications occurred. To our knowledge, this is the first report describing this technique specifically in patients less than 36 months of age.
In a new process for the prodn. of an antirheumatic medicament, normal horse serum is clarified by centrifugation, diluted 1:8 to 1:10 with distilled water, adjusted to acidic pH, and heated 30-180 mins. in a boiling water bath; the heating (followed by centrifugation) is repeated 1-3 times; and the supernatant obtd. is stabilised with a preserving agent and diluted with a salt soln. so as to give an NaCl concn. of 0 15M and an acidic pH. The prod. has antirheumatic and anti-inflammatory properties and is free from the disadvantages of known antiinflammatory agents.
PCT No. PCT/ES94/00006 Sec. 371 Date Nov. 9, 1994 Sec. 102(e) Date Nov. 9, 1994 PCT Filed Jan. 21, 1994 PCT Pub. No. WO94/17098 PCT Pub. Date Aug. 4, 1994An immunogenic peptide for use in the prevention of parvovirus infections having a contiguous sequence of 6 to 25 amino acids. The peptide is produced from autonomous parvoviruses so as to be capable of inducing neutralizing antibodies against such viruses. These peptides correspond to antigenic sites located in the first 25 amino acids of the amino terminal end of the VP2 proteins of parvoviruses. When these peptides are coupled to carrier proteins or to other immunogenic complexes, they can be used in the formulation of vaccines appropriate to protect dogs, cats, pigs and minks against the infections caused by the parvoviruses.
FIELD: medicine. SUBSTANCE: method involves selecting Laminaria saccharina aged 1-2 years with stem length not less than 15 cm. The stems are rinsed three times in fresh water in 1:2 proportion at a temperature not higher than 14 C. The washed stems are stretched on a frame and stitched with silk or lavsan threads every 5.5-6 cm leaving free thread ends at least 5 cm long. The stems are dried at a temperature not higher than 80 C in actively blowing air through during 1 day. Knots are made on the threads and the dried stems are cut into bars. Sharp ends are smoothed, thread is wound around the bar and fixed with plastic ring. Ready bars are packed into double envelopes made from polyethylene-like material and subjected to sterilization. EFFECT: ecological purity; excluded allergic reactions; lower price.
For Intravesical Use Only. Do NOT administer by subcutaneous or intravenous or intramuscular routes.

  * For induction: ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 6 weeks. A second induction course may be administered if complete response is not achieved at month 3.
  * For maintenance: After BCG and ANKTIVA induction therapy, ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19 (for a total of 15 doses). For patients with an ongoing complete response at month 25 and later, maintenance instillations with BCG may be administered once a week for 3 weeks at months 25, 31, and 37 for a maximum of 9 additional instillations.



The recommended duration of treatment is until disease persistence after second induction, disease recurrence or progression, unacceptable toxicity, or a maximum of 37 months.
Allergic asthma is an important public health problem and is a complicated respiratory sickness that is characterized by bronchial inflammation, bronchoconstriction, and breathlessness. Asthma is orchestrated by type 2 immune response and remodeling is one of the important outputted problem in chronic asthma. Thymol is a naturally occurring monocyclic phenolic, it has a series of biological properties, and its immunomodulatory and anti-remodeling effects on allergic asthma were evaluated. The OVA-LPS-induced asthmatic mice were treated with thymol. Methacholine challenge test, eosinophil count, and levels of IL-4, IL-5, IL-13, and IL-33 in bronchoalveolar lavage fluid, total and OVA-specific IgE levels in serum, remodeling factors, gene expression of TGF-β, Smad2, Smad3, and lung histopathology were done. Treatment with thymol could control AHR, eosinophil percentage levels of Th2 cytokines and Igs, remodeling factors, expression of TGF-β, Smad2 and Smad3 genes, inflammation, goblet cell hyperplasia, and mucus production in asthmatic mice. Thymol can control asthma pathogens and related remodeling and fibrosis bio-factors and can be a potential treatment of asthma.
1. Liquefied (or Liquified) Phenol USP (Carbolic Acid Liquefied) is Phenol maintained in a liquid condition by the presence of 10.0% water. Its topical medical use includes P & A (Phenol & Alcohol) procedures, and other procedures necessitating an anesthetic antiseptic, solvent, or cauterant. In treating ingrown nails, it is applied to the nail bed to prevent regrowth of nails. As a colorless solution, it can be difficult to see where an application is going during a procedure. Phenol with color eliminates this problem by creating a readily visible way of identifying where the application is going. 
     2. The patent calls for recognition of our innovation to mix Phenol with color for visual enhancement for physicians or others. “Phenol with color” is thus the innovation being patented and not the actual name of a product.
Conventional drug treatment in Malaysia and Southeast Asia including detention for an average of 2 years, including educational and job skills programs and physical education. Medical therapies for treating substance use disorders, such as opioid-agonist treatment (OAT), are unavailable.
The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.
PROBLEM TO BE SOLVED: To obtain a controlled release preparation which can be stored long term at room temperature by suppressing the coagulation of a microsphere by adding a specific amount of saccharide and heating when frozen drying the microsphere of a medicine using an in vivo degradable polymer. SOLUTION: This preparation is obtained by frozen drying a microsphere obtained from a water in oil type emulsion containing a solution of a bioactive peptide, an inner water phase, and polylactic acid having approximately 5000-25000 of weight average molecular weight, as oil phase, after adding approximately 2-60wt.% of saccharide. Then heated at the temperature approximately 20 deg.C higher than the glass transition temperature of the microsphere for about 24-120 hours. The peptides of the formula [R1 is His, Tyr, etc., R2 is Tyr, etc., R3 is Gly, etc., R4 is Leu, etc., R5 is Gly-NH-R6 (R6 is H, an alkyl), etc.] or its salt is preferable as the bioactive peptide. D-mannitol, sodium alginate, fructose, dextrin, dextran, sucrose, sorbitol, etc., is preferred as saccharide.
Group 2. Gonadal veins embolozation This group includes patients who underwent embolization of the gonadal veins with coils.
Treatment will be administered by licensed practitioners with over five years of experience, in separate rooms to prevent patient interaction. The selected acupuncture points include LI11 , SP10, ST36, SP6, LR3, LI4, ST25, CV4, GV20, and superior GV29. Sterile disposable stainless-steel needles (0.3 mm×40 mm; Hwato brand, Suzhou Medical Appliance Factory, Suzhou, China) will be used. Patients will lie supine, and routine skin sterilization will be performed locally. Needles will be inserted at depths ranging from 10 to 30 mm at the designated acupuncture points. Each needle will be manually manipulated with lifting, thrusting, twirling, and rotating to elicit Deqi sensation (including soreness, numbness, distention, and heaviness). Needles will remain inserted for 30 minutes per session and manipulated three times, every 10 minutes. Acupuncture sessions will be conducted three times weekly over a six-week period.
There have been post-marketing reports of acute pancreatitis in patients taking saxagliptin. In a cardiovascular outcomes trial enrolling participants with established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors for ASCVD (SAVOR trial), cases of definite acute pancreatitis were confirmed in 17 of 8240 (0.2%) patients receiving saxagliptin compared to 9 of 8173 (0.1%) receiving placebo. Pre-existing risk factors for pancreatitis were identified in 88% (15/17) of those patients receiving saxagliptin and in 100% (9/9) of those patients receiving placebo. 

After initiation of KOMBIGLYZE XR, observe patients for signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue KOMBIGLYZE XR and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using KOMBIGLYZE XR.
In this issue, a special section is dedicated to the factors affecting senescence. It examines the interplay between immunosenescence and chronic kidney disease, probes into Peto's paradox, and explores how epigenetic switches can potentially mitigate senescence and inflammation. Additionally, insights are offered on understanding a specific Ras mechanism in yeast for potential therapeutic interventions against cancer and for longevity. Furthermore, the remarkable endurance of last year's Nobel Prize winner in Physiology or Medicine is also highlighted. Moreover, the discovery of potential biomarkers for hepatocellular carcinoma, the link between osteoarthritis and the circadian clock, and the multifaceted role of DNAJA3 in B cell lifecycle are discussed. Further, study findings shed light on the influence of extracellular matrix molecules on cleft palate formation, the renal protective effects of combination therapy in diabetic kidney disease, and novel approaches to detect developmental dysplasia of the hip. Finally, a correspondence delves into the role of autonomic regulation in cognitive decline.